Sort
25,944 grants matching “neurodegeneration”
Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease
$11,038,947Gary E Gibson · Winifred Masterson Burke Med Res Inst · R01 · FY2023 · AG
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study
$11,000,000Susan Abushakra · Alzheon, Inc. · R01 · FY2022 · AG
Clinical Core
$10,939,222Paul S. Aisen · Northern California Institute/Res/Edu · U19 · FY2022 · AG
Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease
$9,664,204Gary E Gibson · Winifred Masterson Burke Med Res Inst · R01 · FY2022 · AG
Metformin in Alzheimer's dementia Prevention (MAP)
$9,597,463Jose A Luchsinger · Columbia University Health Sciences · R01 · FY2021 · AG
Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease
$9,592,233Gary E Gibson · Winifred Masterson Burke Med Res Inst · R01 · FY2025 · AG
Amyloid Imaging, VMCI, and Analysis for ADNI
$9,261,188Michael W Weiner · Northern California Institute/Res/Edu · RC2 · FY2009 · AG
HABS-HD - Core D - Omics Core
$9,180,539Robert A Rissman · University Of North Texas Hlth Sci Ctr · U19 · FY2022 · AG
Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations
$9,157,485Nilufer Ertekin-Taner · Mayo Clinic Jacksonville · U19 · FY2025 · AG
Health and Aging Brain among Latino Elders (HABLE-AT(N)) Study
$9,147,291Sid E O'Bryant · University Of North Texas Hlth Sci Ctr · R01 · FY2020 · AG
Health and Aging Brain among Latino Elders (HABLE-AT(N)) Study
$9,074,729Sid E O'Bryant · University Of North Texas Hlth Sci Ctr · R01 · FY2023 · AG
Health and Aging Brain among Latino Elders (HABLE-AT(N)) Study
$9,074,729Sid E O'Bryant · University Of North Texas Hlth Sci Ctr · R01 · FY2022 · AG
Health and Aging Brain among Latino Elders (HABLE-AT(N)) Study
$9,059,887Sid E O'Bryant · University Of North Texas Hlth Sci Ctr · R01 · FY2021 · AG
HABS-HD - Core D - Omics Core
$8,962,105Sid E O'Bryant · University Of North Texas Hlth Sci Ctr · U19 · FY2023 · AG
Health and Aging Brain among Latino Elders (HABLE-AT(N)) Study
$8,926,202Sid E O'Bryant · University Of North Texas Hlth Sci Ctr · R01 · FY2025 · AG
Alzheimer's Disease Sequencing Project Phenotype Harmonization Consortium
$8,518,767Timothy J Hohman · Vanderbilt University Medical Center · U24 · FY2024 · AG
Alzheimer's Disease Sequencing Project Phenotype Harmonization Consortium
$8,370,718Timothy J Hohman · Vanderbilt University Medical Center · U24 · FY2025 · AG
IUSM TREAT-AD Center
$8,323,362Alan D. Palkowitz · Indiana University Indianapolis · U54 · FY2025 · AG
Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations
$8,291,222Nilufer Ertekin-Taner · Mayo Clinic Jacksonville · U19 · FY2024 · AG
Early Onset AD Consortium - the LEAD Study (LEADS)
$8,285,753Liana G Apostolova · Indiana University Indianapolis · U01 · FY2018 · AG
Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations
$8,248,338Nilufer Ertekin-Taner · Mayo Clinic Jacksonville · U19 · FY2023 · AG
Metformin in Alzheimer's dementia Prevention (MAP)
$8,176,191Jose A Luchsinger · Columbia University Health Sciences · R01 · FY2023 · AG
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)
$8,066,994John Alam · Eip Pharma, Inc. · R01 · FY2024 · AG
Bridge Funding for Dominantly Inherited Alzheimer Network
$7,994,551Randall J Bateman · Washington University · U19 · FY2025 · AG
A Washington University Gnotobiotic Research, Education and Transgenic (WU-GREaT) center for modeling genetic and environmental effectors of disease pathogenesis
$7,972,413Mark E. Lowe · Washington University · C06 · FY2019 · OD